Skip to content
Inhalation Capsule Allopathic

Trihale 25 mcg+62.5 mcg+100 mcg inhalation capsule

Generic: Vilanterol + Umeclidinium + Fluticasone Furoate

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength25 mcg+62.5 mcg+100 mcg
PackBox of 30: 3600.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per inhalation capsule. Ask your pharmacist before you switch brands.

Vilanterol + Umeclidinium + Fluticasone Furoate 25 mcg+62.5 mcg+100 mcg inhalation capsules

Prices as listed on BestinMeds.

2 brands listed
Trelanti, box of 1090.00 taka per inhalation capsule
Trihale, box of 30 (this medicine)120.00 taka per inhalation capsule

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Vilanterol + Umeclidinium + Fluticasone Furoate guide

Indications

COPD This is indicated in- For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). For the maintenance treatment of asthma in patients aged 18 years and older.

Dosage and administration

Adults: 18 years or older: For oral inhalation only. Should be taken by revolizer. Should be used at the same time every day, not more than 1 time every 24 hours. If shortness of breath or other asthma symptoms arise in the period between doses, an inhaled SABA should be taken for immediate relief. Maintenance treatment of COPD: 1 inhalation of cozycap once daily. Maintenance treatment of asthma: 1 inhalation of cozycap once daily. Limitation of use: Not indicated for relief of acute bronchospasm.

Side effects

COPD: Most common adverse reactions (incidence ≥1%) are upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain, arthralgia, infuenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, oropharyngeal pain, cough, and dysphonia. Asthma: Most common adverse reactions (incidence ≥2%) are pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper respiratory tract infection, bronchitis, respiratory tract infection/viral respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection, rhinitis, infuenza, headache, and back pain.

Precautions and warnings

LABA monotherapy increases the risk of serious asthma-related events. Do not initiate in acutely deteriorating COPD or asthma. Do not use to treat acute symptoms. Do not use in combination with additional therapy containing a LABA because of risk of overdose. Candida albicans infection of the mouth and pharynx may occur. Monitor patients periodically. Advise the patient to rinse his/her mouth with water without swallowing after inhalation to help reduce the risk. Increased risk of pneumonia in patients with COPD. Monitor patients for signs and symptoms of pneumonia. If paradoxical bronchospasm occurs, discontinue and institute alternative therapy. Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation. Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.

Pregnancy and lactation

Insufficient data on the use of this preparation in pregnant women and lactating mothers.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250